Literature DB >> 23056873

Interstitial lung disease in a patient with chronic granulomatous disease.

Mozhgan Moghtaderi1, Sara Kashef, Nima Rezaei.   

Abstract

BACKGROUND: Chronic granulomatous disease (CGD) is an inherited phagocytes defect, characterized by defects of NADPH-oxidase and inability of bacterial killing, which leads to recurrent life-threatening infections. Respiratory problems, which are the major cause of morbidity in CGD, usually result from recurrent severe infections; however, vigorous inflammatory response could also cause respiratory diseases. CASE
PRESENTATION: Herein, an 11 year-old patient with CGD is presented who suffered from chronic cough and dyspnea for 7 years. Considering the results of chest X-ray, high-resolution computed tomography, and pulmonary function test, the diagnosis of interstitial lung disease was made.
CONCLUSION: Early recognition of manifestations associated with CGD and appropriate treatment could prevent further complications and reduce morbidity and mortality in this group of patients.

Entities:  

Keywords:  Chronic Granulomatous Disease; Immunodeficiency; Interstitial Lung Disease

Year:  2012        PMID: 23056873      PMCID: PMC3448230     

Source DB:  PubMed          Journal:  Iran J Pediatr        ISSN: 2008-2142            Impact factor:   0.364


Introduction

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder, which is caused by defects in superoxide generation and phagocytes function. Subsequent defect of bacterial killing leads to cytokine release and inflammation of different organs in the patients with CGD [1-3]. Involvement of respiratory system is one of the main characteristics of patients with CGD. The majority of CGD patients suffer from respiratory disease, including pneumonia, lung abscess, and pulmonary fibrosis. Interstitial lung disease (ILD) is a rare pulmonary condition in this group of patients which causes derangements of the alveolar walls and loss of functional alveolar capillary units leading to restrictive lung disease. Typical features of ILD include the presence of diffuse infiltrates on chest radiograph, and abnormal pulmonary function test (PFT) with evidence of a restrictive defect and/or impaired gas exchange [4]. Exposure-related ILD, systemic disease-associated ILD, alveolar structure disorder-associated ILD, and idiopathic ILD in older children are generally considered as the main causes of ILD in children [5]. ILD could be as a result of recurrent life-threatening infections, whereas non-infectious inflammation could also be responsible for such lung disease. Herein, we present a CGD child complicated with ILD.

Case Presentation

An 11 year-old boy was diagnosed with CGD in infancy, following severe recurrent lower respiratory tract infections. There was no history of primary immunodeficiency disease in his family. The patient gradually developed hypoxia, dyspnea on exertion, cyanosis and became worse during childhood. There were some evidences of repeated pneumonia and consequently using intravenous antibiotics in his past medical history. At the time of his admission to our clinic, he had not fever, but physical examination revealed tachypnea, crackles, retraction, and increased anteroposterior diameter of chest. Laboratory findings, including complete cell blood count (CBC), ESR, liver function test, sweat chloride test and serum immunoglobulin levels were normal. Arterial blood gas (ABG) analysis showed: pH 7.28, O2 saturation 64.7% and PCO2 54.3 mmHg. Blood cultures and tracheobronchial secretion cultures for pyogenic, fungal and mycobacterial infections were negative. Polymerase chain reaction (PCR) for Aspergillus and Candida albicans was negative. Diagnostic bronchoalveolar lavage (BAL) was performed to obtain specimens for cytology and culture. The smear of BAL showed many isolated bronchial epithelial cells accompanied with few inflammatory cells. Nitroblue-tetrazolium (NBT) dye test was defective. The result was compatible with diagnosis of CGD, which was also further confirmed by dihydro rhodamine123 (DHR) dye test. Serial plain chest X-rays showed increased vascular and interstitial markings. The Result of high-resolution computed tomography (HRCT) scan revealed ground glass appearance in both lung fields with some areas of decreased attenuation, honeycombing, asymmetric emphysematous change and increased interstitial marking, which was compatible with diagnosis of interstitial lung disease (Fig. 1).
Fig. 1

High resolution CT scan of the patient revealed ground glass appearance and emphysematous change

High resolution CT scan of the patient revealed ground glass appearance and emphysematous change In PFT, forced expiratory volume in 1 second (FEV1) was decreased to 38.7%; residual volume (RV) and total lung capacity were increased to 773.2% and 203.8%, respectively. The result of PFT was air trapping and high airway resistance in favor of restrictive pattern and destructive lung disease. Echocardiography revealed normal systolic and diastolic function without pulmonary hypertension. For excluding systemic disease-associated interstitial lung diseases, IgM rheumatoid factor, serum antinuclear antibodies reactive to nuclear (ANA), cytoplasmic antigens, anti smooth muscle antibody as well as serum angiotensin-converting enzyme level were measured, which were all normal. After considering ILD in the patient, prednisolon therapy was initiated at a dose of 1 mg/kg/day associated with hydroxychloroquine. At the time of discharge, 30 days after admission, clinical respiratory findings such as cough and dyspnea subsided. After a 3-month course of prednisolone and tapering the dosage, an increased oxygenation at rest and sleep was achieved. Such treatment leads to improvement of pulmonary disease in the patient.

Discussion

Chronic granulomatous disease (CGD) is an inherited immunodeficiency disease, which is generally considered as a rare disease, but its frequency, especially its autosomal recessive form, seems to be much higher in the regions with high rate of consanguinity [6-8]. Although several organs could be affected in CGD, the most common site of involvement is lung [3, 6]. ILD is characterized by thickening of the alveolar walls by a wide spectrum of inflammatory cells, immunoregulatory cells and/or fibrosis, accompanied by loss of functional alveolar capillary unit [5]. Diagnostic procedures could be used to detect ILD, including chest X-ray, HRCT, bronchoalveolar lavage, PFT, and sometimes thoracoscopic lung biopsy[9]. Etiology of ILD encompasses a group of known and unknown disorders in children, but infections account for many cases of known etiologies. After considering ILD, an etiological diagnostic approach is required. A careful history and serum levels of antibodies is needed for eliminating exposure-related ILD and systemic disease-associated ILD, respectively. Among disorders affecting the alveolar epithelium and the alveolar space, viral infections is mainly suggested in pathogenesis of ILD[10]. In CGD patients, microorganisms can be protected from intracellular killing, which consequently leads to leukocyte accumulation, cytokine release and inflammation[11]. In spite of the fact that laboratory findings and BAL specimens revealed no sign of bacterial, mycobacterial, and fungal infection, there was no further adequate facilities for diagnosis of respiratory viral infections in the patient. Idiopathic ILD with unknown etiology may be seen even in CGD, but the reason for non-infectious inflammation remains mostly elusive. Recent studies demonstrated that genes encoding polymorphonuclear cells in CGD patients have an increased expression of pro-inflammatory molecules and decreased anti-inflammation mediators. Key regulators of apoptosis, inflammation and host defense were differentially expressed in the absence or presence of reactive oxygen species, respectively [12]. Although CGD patients have increased susceptibility to infections, a higher incidence of sterile inflammatory disorders in these patients has also been noted. Although a favorable response to corticosteroid therapy can be expected in about 50% of cases, significant sequels such as need for long-term oxygen therapy are often observed[13].

Conclusion

In this report, a rare complication of ILD in a child with CGD has been reported which could be resulted as of either viral or non-infectious etiology. Early diagnosis of lung disease in an immunodeficient patient and appropriate management can prevent further complications, such as pulmonary fibrosis in this group of patients.
  13 in total

1.  Factors influencing survival in children with chronic interstitial lung disease.

Authors:  L L Fan; C A Kozinetz
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

2.  Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry.

Authors:  Nima Rezaei; Zahra Pourpak; Asghar Aghamohammadi; Abolhassan Farhoudi; Masoud Movahedi; Mohammad Gharagozlou; Bahram Mirsaeid Ghazi; Lida Atarod; Kamran Abolmaali; Maryam Mahmoudi; Davoud Mansouri; Saba Arshi; Naser Javaher Tarash; Roya Sherkat; Reza Amin; Sara Kashef; Reza Farid Hosseini; Iraj Mohammadzadeh; Mehrnaz Sadeghi Shabestari; Mohammad Nabavi; Mostafa Moin
Journal:  Am J Reprod Immunol       Date:  2006-08       Impact factor: 3.886

3.  Chronic granulomatous disease. Report on a national registry of 368 patients.

Authors:  J A Winkelstein; M C Marino; R B Johnston; J Boyle; J Curnutte; J I Gallin; H L Malech; S M Holland; H Ochs; P Quie; R H Buckley; C B Foster; S J Chanock; H Dickler
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

Review 4.  Genetic, biochemical, and clinical features of chronic granulomatous disease.

Authors:  B H Segal; T L Leto; J I Gallin; H L Malech; S M Holland
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

6.  Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease.

Authors:  Scott D Kobayashi; Jovanka M Voyich; Kevin R Braughton; Adeline R Whitney; William M Nauseef; Harry L Malech; Frank R DeLeo
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

Review 7.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

8.  Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry.

Authors:  Masoud Movahedi; Asghar Aghamohammadi; Nima Rezaei; Nikrad Shahnavaz; Ali Babaei Jandaghi; Abolhasan Farhoudi; Zahra Pourpak; Mostafa Moin; Mohammad Gharagozlou; Davoud Mansouri
Journal:  Int Arch Allergy Immunol       Date:  2004-06-01       Impact factor: 2.749

Review 9.  Pediatric interstitial lung disease revisited.

Authors:  Leland L Fan; Robin R Deterding; Claire Langston
Journal:  Pediatr Pulmonol       Date:  2004-11

10.  Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry.

Authors:  Nima Rezaei; Asghar Aghamohammadi; Mostafa Moin; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Lida Atarod; Bahram Mirsaeid Ghazi; Anna Isaeian; Maryam Mahmoudi; Kamran Abolmaali; Davoud Mansouri; Saba Arshi; Naser Javaher Tarash; Roya Sherkat; Hedayat Akbari; Reza Amin; Abdolvahab Alborzi; Sara Kashef; Reza Farid; Iraj Mohammadzadeh; Mehrnaz Sadeghi Shabestari; Mohammad Nabavi; Abolhassan Farhoudi
Journal:  J Clin Immunol       Date:  2006-10-06       Impact factor: 8.542

View more
  1 in total

1.  Early Identification of Lung Fungal Infections in Chronic Granulomatous Disease (CGD) Using Multidetector Computer Tomography.

Authors:  Maria Pia Bondioni; Vassilios Lougaris; Giuseppe Di Gaetano; Tiziana Lorenzini; Annarosa Soresina; Francesco Laffranchi; Diego Gatta; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2016-10-21       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.